Variables | Present with HMCAS | ||
---|---|---|---|
Yes(n = 180) | No(n = 314) | P value | |
Characteristics | |||
 Age (in yrs., mean ± SD) | 67.9 ± 13.6 | 66.4 ± 13.8 | 0.262 |
 Male (n, %) | 91 (50.6) | 187 (59.6) | 0.052 |
Risk Factors, n (%) | |||
 Hypertension | 90 (50.0) | 177 (56.4) | 0.172 |
 Diabetes mellitus | 41 (22.8) | 72 (22.9) | 0.969 |
 Atrial fibrillationa | 103 (57.2) | 100 (31.8) | < 0.001 |
 Coronary heart disease | 20 (11.1) | 23 (7.3) | 0.151 |
 Previous stroke/TIA | 17 (9.4) | 49 (15.6) | 0.053 |
 Dyslipidemia | 19 (10.6) | 45 (14.3) | 0.229 |
 Current smoking | 28 (15.6) | 45 (14.3) | 0.712 |
Premorbid Drug Use, n (%) | |||
 Antithrombotic | 21 (11.7) | 22 (7.0) | 0.077 |
 Antiplatelet | 11 (6.1) | 25 (8.0) | 0.446 |
 Statin | 11 (6.1) | 17 (5.4) | 0.747 |
 Antihypertensive | 61 (33.9) | 114 (36.3) | 0.589 |
 Antidiabetics | 15 (8.3) | 34 (10.8) | 0.372 |
Laboratory Studies, mean ± SD | |||
Systolic blood pressurea, mmHg | 140.2 ± 23.3 | 147.0 ± 25.8 | 0.004 |
 Temperature, oC | 36.5 ± 0.5 | 36.4 ± 0.3 | 0.058 |
 Blood glucose, mmol/L | 8.0 ± 2.7 | 8.1 ± 3.1 | 0.675 |
 Triglycerides, mmol/L | 1.5 ± 1.0 | 1.7 ± 1.2 | 0.111 |
 Total cholesterol, mmol/L | 4.3 ± 1.1 | 4.3 ± 1.1 | 0.684 |
 HDL-C, mmol/L | 1.3 ± 0.4 | 1.3 ± 0.4 | 0.661 |
 LDL-C, mmol/L | 2.6 ± 1.0 | 2.5 ± 0.8 | 0.539 |
 Serum uric acid, μmol/L | 350.3 ± 101.1 | 354.8 ± 106.0 | 0.640 |
 White cell count (*10^9/L) | 8.8 ± 3.0 | 8.5 ± 8.9 | 0.639 |
 Serum creatinine, μmol/L | 74.0 ± 23.2 | 78.7 ± 35.3 | 0.112 |
 NIHSS score at admissiona (median, IQR) | 16 (11-20) | 7 (3-15) | < 0.001 |
 Proximal occlusiona | 135 (75.0) | 159 (50.6) | < 0.001 |
Collateral Status, n (%) | |||
 rLMC 0-10a | 121 (67.2) | 72 (22.9) | < 0.001 |
 rLMC 11-16 | 37 (20.6) | 64 (20.4) | 0.963 |
 rLMC 17-20a | 22 (12.2) | 178 (56.7) | < 0.001 |
Reperfusion therapy, n (%) | |||
 Thrombolysis | 41 (22.8) | 78 (24.0) | 0.606 |
 Onset-to-treatment time (r-tPA), min | 191.1 ± 43.3 | 182.2 ± 48.1 | 0.338 |
 Endovascular treatment | 51 (28.3) | 31 (9.9) | < 0.001 |
 Onset-to-treatment time, min | 269.9 ± 117.0 | 215.3 ± 73.2 | 0.062 |